ASCO 2018

ALL

View all

3:13

Tisagenlecleucel in ALL: follow-up data and insights

Stephan Grupp • 1 Jun 2018

2:31

Improving the SOC for ALL with inotuzumab

Ryan Cassaday • 1 Jun 2018

AML

View all

1:44

A worldwide Phase III trial treating AML with pracinostat

Guillermo Garcia-Manero • 1 Jun 2018

1:48

IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

Daniel Pollyea • 1 Jun 2018

CAR T-cells

One of the most highly anticipated areas of research at ASCO 2018, CAR T-cells represent an exciting treatment option across a range of hematological malignancies.

Find out about the latest CAR T-cell therapies, toxicity and management data, role in transplant, and the future of the field.

CLL

View all

3:30

Moxetumomab pasudotox and hairy cell leukemia: results of a pivotal study

Robert Kreitman • 1 Jun 2018

1:46

Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib

Peter Hillmen • 1 Jun 2018

Lymphoma

View all

1:32

Choosing the best treatment for your follicular lymphoma patient

Nathan Fowler • 1 Jun 2018

5:52

Updated safety & durability results for CAR-T lisocabtagene maraleucel in NHL

Jeremy Abramson • 1 Jun 2018

Measurable Residual Disease

MRD is gaining traction as both a prognostic indicator and a biomarker for treatment strategizing.

A key field of interest in hemonc, MRD was much-discussed at ASCO 2018. Topics included using MRD in the clinical setting, relevance in transplant, and use of MRD as a clinical trial endpoint.